Surging global incidence of advanced solid tumors such as breast, prostate, and lung cancers prone to skeletal dissemination, expanding geriatric populations vulnerable to skeletal-related events (SREs) like pathologic fractures and spinal cord compression, and continuous biopharmaceutical innovations in bisphosphonates, RANK ligand inhibitors, and targeted radiopharmaceuticals are driving...